Submitted by D.P. Juan on Wed, 03/12/2025 - 10:34
Congratulations to Dr. Ana Rossi, Dr. Yasunori Watanabe and Prof. Mark Howarth for their recent funding success for developing orally administered antibody mimetics through their spin-out company, Gastrobody Therapeutics. This funding includes UKRI Proof of Concept, Wellcome Trust Access to Expertise, and Technology Investment Fund (Cambridge Enterprise) grants.
The antibody mietics, termed Gastrobodies, are resilient to the harsh environment in the GI tract. The gastrobody protein scaffold is derived from a naturally occurring soybean protein with protein loops that can be engineered to bind and recognise any feasible target.
More information on the spinout company can be found on their webpage: https://lnkd.in/eCWWQiDU